Hovione's 'world's first' innovative inhaler receives prestigious design award

The 8Shot DPI is capable of delivering high doses of drug to the lungs.
Hovione Technology's 8Shot dry powder inhaler (DPI) enabling high dose drug delivery to the lungs has received the Red Dot 2020 Product Design Award in the Healthcare Daily Living AIDS category.
8Shot is the world’s first 8-puff, disposable DPI enabling drug delivery of new pharmaceutical compounds requiring very high doses delivered to the lungs.
The device is suitable for inhaled delivery of biologics, antibiotics, anti-viral, vaccines, pain or rescue treatments of doses up to 400 mg formulated as drug alone or engineered particles in multiple, sequential inhalation maneuvers for maximum therapeutic benefit and patient safety.
“We are extremely proud and delighted to accept the Red Dot Product Design Award, together with our design and development partner WeADD,” said Dr João Ventura Fernandes, Hovione Technology’s Director of Technology Development and Licensing.
“The 8Shot DPI is uniquely positioned to make available off-the-shelf to pharmaceutical companies a patented high payload DPI to deliver inhaled biologics, antibiotics, anti-virals, vaccines, pain or rescue treatments requiring high-dose drug delivery.”

Related News
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease. -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries. -
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance